Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerexa Inc.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Heads of vaccines development at partners GSK and Sanofi:“This is not a sprint, it’s a marathon.”
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.